Bristol-Myers Squibb Co (NYSE:BMY) Shares Purchased by New England Asset Management Inc.

Share on StockTwits

New England Asset Management Inc. boosted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 17.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 62,700 shares of the biopharmaceutical company’s stock after acquiring an additional 9,455 shares during the quarter. New England Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $2,843,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Lodestar Investment Counsel LLC IL lifted its holdings in Bristol-Myers Squibb by 5.2% in the 2nd quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock valued at $5,157,000 after purchasing an additional 5,579 shares in the last quarter. Perella Weinberg Partners Capital Management LP lifted its holdings in Bristol-Myers Squibb by 10.9% in the 1st quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock valued at $99,000 after purchasing an additional 1,905 shares in the last quarter. Cypress Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 21.2% in the 2nd quarter. Cypress Capital Management LLC now owns 154,335 shares of the biopharmaceutical company’s stock valued at $6,999,000 after purchasing an additional 26,990 shares in the last quarter. Stephens Inc. AR lifted its holdings in Bristol-Myers Squibb by 30.7% in the 1st quarter. Stephens Inc. AR now owns 216,532 shares of the biopharmaceutical company’s stock valued at $10,331,000 after purchasing an additional 50,798 shares in the last quarter. Finally, Nachman Norwood & Parrott Inc lifted its holdings in Bristol-Myers Squibb by 3.5% in the 2nd quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock valued at $2,285,000 after purchasing an additional 1,687 shares in the last quarter. 80.16% of the stock is currently owned by hedge funds and other institutional investors.

BMY has been the topic of several analyst reports. Goldman Sachs Group initiated coverage on Bristol-Myers Squibb in a report on Tuesday, May 28th. They set a “buy” rating and a $54.00 price target on the stock. UBS Group reduced their price target on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a report on Thursday, June 13th. ValuEngine upgraded Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Monday, August 26th. TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday. Finally, Bank of America lifted their price target on Bristol-Myers Squibb from $46.00 to $49.00 and gave the stock a “neutral” rating in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $55.74.

BMY traded up $0.50 on Friday, hitting $50.57. The company had a trading volume of 12,880,464 shares, compared to its average volume of 9,166,953. The firm has a market cap of $81.56 billion, a P/E ratio of 12.71, a PEG ratio of 2.45 and a beta of 0.70. Bristol-Myers Squibb Co has a 1 year low of $42.48 and a 1 year high of $63.69. The company’s fifty day moving average price is $47.67 and its 200 day moving average price is $47.08. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.12. The firm had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. Bristol-Myers Squibb’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.01 EPS. On average, analysts predict that Bristol-Myers Squibb Co will post 4.29 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be issued a $0.41 dividend. The ex-dividend date is Thursday, October 3rd. This represents a $1.64 annualized dividend and a yield of 3.24%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.

In other news, Director Robert J. Bertolini bought 11,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was bought at an average cost of $44.72 per share, with a total value of $491,920.00. Following the transaction, the director now directly owns 11,397 shares in the company, valued at approximately $509,673.84. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: Diluted Earnings Per Share

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report